Citations

Clear

127 citation(s) found for "Shari, G".

Elliptical Stages in Mohs Micrographic Surgery; A Retrospective Cohort Study
Smith, Sarah E. B. , Keith, Debra, Girardo, Marlene, Ochoa, Shari, Ochoa, Shari A.

Mayo Clinic

Dermatologic Surgery | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005297 | PMID 42574232 Get It

Pulmonary Embolism Reporting and Data System (PE-RADS™) v2026 for the Diagnosis of Acute Pulmonary Embolism on CT and MR Angiography
Koweek, Lynne , Agarwal, Prachi , Brosnahan, Shari B. , Bishay, Vivian, Cronin, Paul, François, Christopher J. , Giri, Jay, Litmanovich, Diana , Leung, Ann N. , Koweek, Lynne , François, Christopher , Litmanovich, Diana E , Leung, Ann , Zimmerman, Stefan L , Bhalla, Sanjeev , Bishay, Vivian Lee, Cronin, Paul, Giri, Jay , West, Frances Mae

Mayo Clinic

Radiology | July 21, 2026 | Volume: 320 | Issue: 1 | Pages: No page available

10.1148/radiol.252721 | PMID 42478953 Get It

The Pulmonary Embolism Reporting and Data System (PE-RADS) provides a standardized framework for reporting acute pulmonary embolism at CT and MR angiography to guide treatment considerations based on clot location and right heart imaging features.
Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma
Paiva, Bruno , Manrique, Irene , Thompson, Ethan, CAMPBELL, TIMOTHY B., Guerrero, Camila, Martin, Nathan, Anderson, Larry D. , Lonial, Sagar, Raje, Noopur S., Lin, Yi, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Kaiser, Shari, Paiva, Bruno , Anderson, Larry D , Thompson, Ethan G., Berdeja, Jesús G. , Lonial, Sagar , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C.

Mayo Clinic

HemaSphere | July 2, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/hem3.70423 | PMID 42396130 Get It

Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and computational flow cytometry in 258 bone marrow aspirates from 107 MM patients treated with idecabtagene vicleucel in the KarMMa trial. At screening, there was an association between longer PFS and increased percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs. At Month 1 after infusion, the presence of >1% CAR‐T cells, a CD4/CD8 CAR‐T‐cell ratio >0.09, and greater abundance of non‐activated non‐cytolytic CAR‐T cells identified patients with longer PFS. Notably, 47 of the 115 endogenous T‐cell clusters were prognostic at the latest assessment performed after CAR‐T infusion. Lower percentages of ICOS + TIGIT − Tregs showed the strongest association with longer PFS. Altogether, this large dataset of dynamic immune profiling throughout treatment with anti‐B‐cell maturation antigen (anti‐BCMA) CAR‐T cells uncovered that the T‐cell composition prior to apheresis as well as CAR‐T and endogenous T‐cell phenotypes after infusion associates with PFS. These findings have potential for translation into routine laboratory practice for improved understanding of response and resistance to CAR‐T cells in relapsed/refractory MM.
Clinical Features of Palmoplantar Nonmelanoma Skin Cancers; a Multicenter Retrospective Study
Cumsky, Helen J.L., Smith, Sarah E. B. , Swanson, Leah A. , Ochoa, Shari, Ochoa, Shari A.

Mayo Clinic

Dermatologic Surgery | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005240 | PMID 42335090 Get It

Long-term safety outcomes of pregnancy among young breast cancer survivors: Results from a prospective, multicenter cohort study.
Zheng, Yue, Niman, Samuel M. , Dibble, Kate, Rosenberg, Shoshana M., Ruddy, Kathryn Jean, Gelber, Shari , Tamimi, Rulla, Peppercorn, Jeffrey , Schapira, Lidia, Come, Steven E. , Warner, Ellen, Lambertini, Matteo, Ginsburg, E, Partridge, Ann H., Sorouri, Kimia , Dibble, Kate E. , Rosenberg, Shoshana M. , Kirkner, Gregory J. , Ruddy, Kathryn J. , Tamimi, Rulla, Schapira, Lidia , Borges, Virginia F. , Warner, Ellen , Lambertini, Matteo , Ginsburg, Elizabeth S. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 632-632

10.1200/jco.2026.44.16_suppl.632 Get It

632 Background: Prospective data on the risk of breast cancer (BC) recurrence among young BC survivors who have a subsequent pregnancy are limited. We sought to evaluate the long-term impact of pregnancy and live birth on BC outcomes in the Young Women’s Breast Cancer Study (NCT01468246), a prospective multicenter study of women aged ≤40 years at BC diagnosis. Methods: Women with stage 0-III BC without prior hysterectomy were included. The primary endpoint was breast cancer-free interval (BCFI) between patients with and without a (a) pregnancy and (b) live birth after BC. Secondary endpoints were distant recurrence-free interval (DRFI) and overall survival (OS). A time-varying Cox proportional hazards model was performed by estrogen receptor (ER) status, controlling for age at diagnosis, tumor stage, HER2 status, tumor grade, parity at diagnosis, and germline pathogenic variant status. Results: Among 1,016 BC survivors at a median follow-up of 12 (range, 0.5-18.5) years, 198 reported ≥1 pregnancy and 165 reported ≥1 live birth post-diagnosis. Among survivors who reported a post-diagnosis pregnancy, median age at diagnosis was 32 (range, 17-40) years; most had stage I (35%) or II (40%) BC, with 72% hormone receptor (HR)-positive and 25% HER2+; 42% were nulligravid and 60% were nulliparous at diagnosis. Among BC survivors who did not become pregnant post-diagnosis, median age at diagnosis was 37 (range, 21-40) years; most had stage I (35%) or II (43%) BC, with 75% HR-positive and 28% HER2+; 25% were nulligravid and 29% were nulliparous at diagnosis. Among BC survivors with ER-positive tumors (n = 737), pregnancy after BC was not associated with a difference in BCFI (adjusted hazard ratio [HR] 0.60, 95% CI 0.31-1.16, P = 0.130), DRFI (HR 0.73, 95% CI 0.35-1.55, P = 0.416), or OS (HR 0.58, 95% CI 0.24-1.40, P = 0.227). Similarly, live birth after BC did not impact BCFI (HR 0.83, 95% CI 0.45-1.55, P = 0.560), DRFI (HR 1.04, 95% CI 0.52-2.06, P = 0.923), or OS (HR 0.77, 95% CI 0.34-1.76, P = 0.541). Outcomes among BC survivors with ER-negative tumors (n = 278) were also not affected by post-diagnosis pregnancy (BCFI [HR 1.48, 95% CI 0.70-3.14, P = 0.304], DRFI [HR 1.59, 95% CI 0.68-3.75, P = 0.287], OS [HR 0.99, 95% CI 0.39-2.49, P = 0.975]) or live birth (BCFI [HR 1.02, 95% CI 0.41-2.53, P = 0.974], DRFI [HR 0.80, 95% CI 0.24-2.69, P = 0.722], OS [HR 0.39, 95% CI 0.09-1.69, P = 0.208]). Conclusions: In this multicenter, prospective study with 12 years of median follow-up, pregnancy and live birth after BC did not impact BC events or overall survival, irrespective of ER status. These long-term data from a modern cohort provide reassurance for young BC patients interested in future fertility. Clinical trial information: NCT01468246 .
ABSTRACT NUMBER: ESOC2026A250 MULTIMODALITY IMAGING FOR PATENT FORAMEN OVALE EVALUATION (MAINFRAME)
Knopp, Rachel, Flemming, Kelly, Scharf, Eugene, Keser, Zafer, Prink, Jessica, Johnson, Shari, Reeder, Guy, Brown, R D, Harmsen, William, Khan, Muhib, Flemming, Kelly D. , Scharf, Eugene , Keser, Zafer , Johnson, Shari, Reeder, Guy S.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i135-i136

10.1093/esj/aakag023.225 Get It

Abstract Background and aims Patient foramen ovale (PFO) is a stroke risk factor evaluated using transthoracic echocardiogram (TTE), transesophageal echocardiogram (TEE), transcranial Doppler ultrasound (TCD), and cardiac computed tomography (CCT). TCD is non-invasive, but its diagnostic performance relative to other modalities is unclear. We hypothesized that TCD has high sensitivity but low specificity for PFO detection. Methods We conducted an IRB-approved, single-center retrospective study of patients undergoing TCD for right-to-left shunt (RLS) detection between January 2024 and April 2025. Patients were identified from the Neurosonology Laboratory Quality Database. Records were reviewed for demographics, comorbidities, and TTE, TEE, and CCT findings. Sensitivity, specificity, and positive and negative predictive values were calculated for TCD, TTE, and CCT relative to TEE, the gold standard. The sensitivity and specificity of TCD versus TTE were compared using McNemar test. Results Ninety-two patients were included. Mean age was 52.66 ± 15.78 years, and 51% were female; qualifying events included ischemic stroke or transient ischemic attack. RLS was detected in 53 patients (57.6%) by TCD, 17 (30%) by TTE, 18 (28.5%) by TEE, and 3 (21%) by CCT. TCD demonstrated 94% sensitivity and 53% specificity, (PPV 66%, NPV 89%). TTE showed 50% sensitivity and 82% specificity (PPV: 75%, NPV 61%), while CCT showed 33% sensitivity and 100% specificity (PPV 100%, NPV 33.3%). TCD had significantly higher sensitivity than TTE for RLS detection (p=0.039) with a non-significant difference in specificity (p=0.062), using TEE as the reference. Conclusions TCD has high sensitivity for RLS detection in patients with ischemic stroke or transient ischemic attack. Conflict of interest Rachel Knopp: nothing to disclose; Kelly Flemming: nothing to disclose; Eugene Scharf: nothing to disclose; Zafer Keser: nothing to disclose; Jessica Prink: nothing to disclose; Shari Johnson: nothing to disclose; Guy Reeder: nothing to disclose; Robert Brown: nothing to disclose; William Harmsen: nothing to disclose; Muhib Khan: nothing to disclose Table 1 - belongs to Results
Military-Civilian Partnership to Advance Standards of Performance for Simulated Combat Trauma Medical Skills: Validation of Competency Thresholds
Patel, B. M. , Nicholson, Susannah E. , Okerman, Tiffany S., Lopreiato, Joseph , Tisherman, S A, Frisch, Adam, Noël, P., Poropatich, Ronald , Phrampus, Paul E., Andreatta, Pamela , Athale, Janhave, Bacik, Adam , Jonas, Rachelle B., Brand, Shari, Bowyer, Mark, Butterfield, Duke, Callisen, Hannelisa, Connacher, Hugh, Chung, Yvonne, Colquist, Julie, Davisson, Blake, Gerhardus, Christian , Fitzgerald, Lavana, Phrampus, Paul, Hendrix, Cheralyn, Janicki, Adam, Knott, Camilla, Kunze, Katie, Lopreiato, Joseph, Low, Amy, McLeish, William, McQuillan, Karen , Milaski, Jessie, Mushaben, Mallory, Neustein, Benjamin, Nicholson, Susannah , Okerman, Tiffany, Patel, Bhavesh, Peterson, Paul, Proctor, Jasmine, Puche, Adam, Rorabeck, Janice, Sen, Ayan, Seamans, David, Shusko, Alexander, Sisson, Craig, Skolnick, Aaron, Sorto, Sharon, Tetzlaff, Elizabeth, Tillman, George, Tisherman, Sam, Patel, Bhavesh M , Noël, Pierre, Noel, Pierre, Andreatta, Pamela , Callisen, Hannelisa, Colquist, Julie , Knott, Camilla C., McLeish, William, Noel, Pierre, Rorabeck, Janice Annette, Shusko, Alexander , Thurman, Paul , Tisherman, Samuel A., Yu, Soojie

Mayo Clinic

Military Medicine | February 28, 2026 | Volume: 191 | Issue: Supplement_1 | Pages: 435-443

10.1093/milmed/usag118 | PMID 42560252 Get It

Abstract Introduction Combat casualty care requires standardized proficiency criteria to ensure readiness in austere environments, yet gaps persist in defining performance thresholds for critical trauma skills. The Combat Medical Skills Sustainment Consortium (CMSSC), a novel military-civilian collaboration, aimed to validate competency thresholds for 21 Department of Defense-identified trauma skills. Materials and Methods A prospective cohort study (2022-2025) enrolled 1,495 military and civilian personnel across five academic centers, stratified by experience (novice, intermediate, expert). Skills, including cricothyroidotomy, whole blood transfusion, and ultrasound-guided vascular access, were assessed using validated checklists in Role 2-congruent simulations. Statistical analysis compared checklist performance against participant experience with a priori checklist scores estimated at 40% (novices) and 90% (experts). Results Competency thresholds were established, ranging from 77% (mechanical ventilation) to 100% (handoff). Experts achieved 85%-98% proficiency across most skills, with novices at 34%-97%. A ceiling effect was observed for less complex skills consistent with the power law of practice. Conclusion The Combat Medical Skills Sustainment Consortium validated standardized assessment tools, with potential to address readiness gaps through military-civilian synergy. Findings support consortium-guided curriculum development and highlight the need for longitudinal skill decay studies. Impact This study sets a benchmark for trauma care skills assessment, facilitating rapid adoption across military and civilian settings.
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu-Rustum, Nadeem R, Campos, Susana M. , Amarnath, Sudha R. , Barber, Emma L. , Bradley, Kristin, Brooks, Rebecca , Chon, Hye Sook, Crispens, Marta Ann, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Mantia-Smaldone, Gina , Mariani, Andrea , Mutch, David, Nagel, Christa , Nekhlyudov, Larissa, Nwachukwu, Chika, Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Nwachukwu, Chika , Abu‐Rustum, Nadeem R. , Arend, Rebecca C. , Bradley, Kristin , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Glaser, Gretchen , Landrum, Lisa M. , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 3 | Pages: 101-126

10.6004/jnccn.2026.0011 | PMID 41825134 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many biologic and clinical characteristics with cervical cancer, several management recommendations, particularly systemic therapy, are extrapolated from evidence and practices established for cervical cancer. This guideline excerpt summarizes key components of management, including diagnostic evaluation and workup, principles of staging, pathology considerations, radiation therapy principles, and primary treatment recommendations for both early-stage and advanced disease. It also details approaches to manage relapses, including locoregional recurrence and distant metastases, and provides an in-depth overview of systemic therapy recommendations for vaginal cancer.
P-73. Unique Pathogen Distribution in Patients Undergoing Chronic Antibiotic Suppression for Cardiac Implantable Electronic Device Infection
Zaslow, Shari J. , Baddour, L.M., DeSimone, Daniel C. , Chesdachai, Supavit

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.302 Get It

Abstract Background Cardiac implantable electronic device infection (CIEDI) is a serious complication, occurring in approximately 1% of implantations. In addition to antimicrobial therapy, complete device extraction is considered essential for definitive cure. However, this may not always be feasible due to a variety of factors. In select cases, long-term chronic antibiotic suppression (CAS) has been used, yet clinical characteristics and outcomes of patients who received CAS have scarcely been reported. Methods A descriptive study analyzing all adult (age > 18) patients with definite CIEDI who received CAS between 2016 and 2023 across the Mayo Clinic Enterprise (Arizona, Florida, Minnesota, and Upper Midwest) was conducted. Patients with either ventricular assist devices or fungal infection were excluded. Results A total of 321 patients were diagnosed with definite CIEDI during the study period. A total of 37 (8.7%) patients received CAS due to device retention. The median age was 77.5 [IQR 70.5, 87.5] with 32.4% female. Permanent pacemakers were involved in most (64.9%) infections. Approximately one-third (32.4%) of patients had a prosthetic valve. The median time from initial device implantation to CIEDI was 10.6 years [IQR 4.8, 18.1]. CIED-related infective endocarditis was present in 70.3% of cases and 67.6% had lead involvement. The most commonly isolated organisms were Staphylococcus aureus (29.7%), coagulase-negative staphylococci (27%), Enterococcus faecalis (13.5%) and Streptococci (13.5%). Other pathogens or culture-negative cases comprised 16.3%. The primary reason for device retention and CAS was poor surgical candidacy. Doxycycline was the most commonly used agent for CAS, accounting for 37.8% of cases. The average length of suppression was 469.0 days [IQR158.0, 1264.0]. The rate of relapse was 8.1% with all occurring within 90 days of diagnosis. One year mortality was 27.0%. Conclusion CAS may be a feasible option for patients with device retention, although a small proportion experience CIEDI relapse. Unexpectedly, the pathogen distribution among CAS recipients differed from that seen in a general CIED infection population, highlighting selection bias and the distinct clinical characteristics of patients managed with CAS. Disclosures Larry M. Baddour, MD, UpToDate, Inc.: Royalty payments (authorship duties).
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 549-573

10.6004/jnccn.2025.0057 | PMID 41671440 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cervical Cancer provide diagnostic workup, staging, and various treatment recommendations for cervical cancer based on clinical and surgical staging. This selection from the NCCN Guidelines for cervical cancer specifically focuses on diagnosis and workup, principles of staging and surgery, and primary treatment recommendations for early-stage and advanced disease and provides a detailed overview of systemic therapy recommendations for cervical cancer.